Podcasts about Pharma

Hello, this is your daily dose of news from Onmanorama. Tune in to get updated about the major news stories of the day.See omnystudio.com/listener for privacy information.

“L'hôpital, ce n'est pas qu'un lieu de soin. C'est aussi un acteur stratégique capable d'agir face aux pénuries.” — Walid Ben BrahimDans cet épisode de Pharma minds, je reçois Walid Ben Brahim, le directeur général d'UniHA, le premier groupement d'achats hospitaliers en France.Créée par les hôpitaux eux-mêmes, cette structure publique rassemble plus de 1500 établissements et pèse 8 milliards d'euros d'achats. Son objectif : transformer les achats en un levier de performance, de résilience et de transition pour tout le système de santé.Walid nous prouve que les achats — souvent perçus comme un sujet technique — sont en réalité un outil d'action concret pour relever les défis de l'hôpital d'aujourd'hui.Ce que vous allez apprendre dans cet épisode :✔️ Pénuries de médicaments et de matériel : pourquoi elles s'aggravent et comment UniHA agit à tous les niveaux — coopération européenne, diversification des fournisseurs, compréhension des enjeux industriels.✔️ Décarbonation du système de santé : 70 % des marchés en 2024 intègrent des critères environnementaux. Objectif : diviser par deux l'empreinte carbone des achats hospitaliers.✔️ Souveraineté sanitaire : relocaliser certaines productions critiques en Europe, avec des investissements ciblés sur les molécules stratégiques, souvent à prix équivalent.✔️ Accès à l'innovation : accompagner l'introduction des médicaments innovants tout en générant des économies grâce aux génériques dès la fin des brevets.✔️ Intelligence artificielle : l'IA comme levier majeur pour fluidifier l'hôpital, optimiser les ressources et remettre du temps là où il compte vraiment : au chevet du patient.✔️ Méthodes agiles et locales : multi-attribution, systèmes d'acquisition dynamiques, ancrage territorial… Des outils concrets pour construire un hôpital plus résilient et plus intelligent.

Revamped Consumer Price Index to provide item-level data for granular approach to policymaking, Virat Kohli starts new innings with a Rs 40 crore investment in sports goods startup Agilitas and Torrent Pharmaceuticals revives talks with KKR to acquire its stake in JB Pharma. We examine the hype vs the returns on thematic mutual funds and tell you about the groundbreaking new stem cell therapy to treat type I diabetes. Tune in.

In the premiere episode of The Executive Dose, host Stephen Beckman—CEO of YARAL Pharma—sits down with Nicholas Hart, CEO of IBSA USA, for a timely and insightful conversation on the forces shaping the pharmaceutical industry in 2025. From supply chain disruption and regulatory pressure to innovation in both branded and generic sectors, these two leaders explore how today's pharma CEOs are steering through uncertainty and preparing for the next wave of transformation. Key Topics Discussed: Introduction to The Executive Dose and its mission to spotlight leadership perspectives in pharma. Stephen Beckman shares his journey leading YARAL Pharma, the U.S.-based generics subsidiary of global healthcare leader IBSA Group.   Hart, CEO of IBSA USA, joins to discuss market dynamics from the branded side of the business. Why this conversation matters in today's complex and rapidly evolving healthcare environment. What's shaping pharma today—global uncertainty, supply chain instability, and shifting regulatory frameworks. The evolving relationship between branded and generic innovation: where the most impact is happening. How executives are leading through volatility while maintaining patient-centric growth strategies. The importance of resilient leadership, cross-sector collaboration, and long-term portfolio planning. Emphasis on strategic alignment, regulatory agility, and mission-driven innovation. Predictions for the next 3–5 years: What will define success in pharma? How R&D, commercialization, and market access are being reimagined. Advice for rising leaders in the pharmaceutical space: Be bold, stay grounded, and lead with purpose. Episode Takeaways: Innovation isn't just about products—it's about mindset, agility, and leadership. Both branded and generic companies have a role in shaping the future of accessible, high-quality care. Strategic foresight and collaboration will define the next era of pharmaceutical growth.

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former FDA official Peter Marks criticized the agency's new risk-based COVID-19 vaccine framework, stating it contradicts the administration's transparency and science standards. The CDC's advisory committee recommended Merck's infant RSV vaccine, and Novavax's approval delay raised concerns about politicization of drug approval processes. Lilly's Verve deal revealed regulatory turmoil following Marks' resignation. Meanwhile, Trump's CDC pick supports vaccine safety, Novartis made a large bet on cardiovascular disease targets, and RFK cut US funding from vaccine alliance Gavi. The biopharma industry is hiring less international talent, and pharma companies face challenges with failed immuno-oncology projects. Evotec is hosting a webinar on preserving quality in the pharmaceutical industry.

In “Supply Chain Reset: Overcoming Pharma & Healthcare Supply Chain Challenges”, Joe Lynch and Michael Needham, a Principal at Efficio, discuss how to build resilient supply chains using data-driven strategies and a hands-on consulting approach to achieve both cost savings and operational resilience in the complex pharma and healthcare sectors. About Michael Needham Michael Needham is a Principal Consultant at Efficio, the leading global consultancy, dedicated to helping clients achieve their supply chain and procurement goals. Michaël has 20+ years of experience working across the pharmaceutical manufacturing, medical device development, healthcare services and CPG sectors. His expertise lies in rapid value creation and turnaround for organizations in financial difficulty. He holds a Bachelor's degree in Economics, Masters in Purchasing & Supply Chain Management and a PhD based on the implementation of lean six sigma process improvement programs across geographic locations. About Efficio For over two decades, Efficio has been a leading independent consultancy, dedicated to helping clients achieve their supply chain and procurement goals. They combine the deep expertise of their consultants with a vast amount of data and insights gained from years of specialized work. Efficio stands out by not just advising, but by embedding with clients to truly understand their unique challenges and deliver tangible, sustained results. Their approach is powered by the Connected Platform and eFlow digital procurement platforms, which leverage global knowledge for smarter, data-driven decisions. Whether it's cost reduction, working capital management, or addressing supply chain complexities, Efficio's singular focus on procurement and supply chain, data-driven technology, and hands-on delivery set them apart. They offer flexible support models, from rapid assessments to long-term partnerships, ensuring measurable and lasting value Key Takeaways: Supply Chain Reset: Overcoming Pharma & Healthcare Supply Chain Challenges In “Supply Chain Reset: Overcoming Pharma & Healthcare Supply Chain Challenges”, Joe Lynch and Michael Needham, a Principal Consultant at Efficio, the leading global consultancy, dedicated to helping clients achieve their supply chain and procurement goals, the following topics were discussed: Optimizing Private Equity Portfolios: Efficio assists private equity clients by optimizing the supply chains of multiple acquired companies within a sector, helping them achieve greater efficiency and economies of scale through consolidation. Collaborative, On-the-Ground Support Works: Efficio's model of “embedding” with clients shows that deep, hands-on collaboration leads to more effective and lasting solutions. Specialization Delivers Results: Efficio's focus on procurement and supply chain proves that specialized expertise is critical for solving complex challenges in sectors like pharma and healthcare. Efficio's Role in Strategic Supply Chain Management: The interview underscored Efficio's expertise in navigating complex supply chain challenges, from geopolitical influences and market consolidation to sustainability initiatives, offering strategic guidance to their diverse client base. Supply Chain Resilience in Pharma & Healthcare: The Efficio consultant highlighted the varying supply chain dynamics for patented versus generic drugs. Generic medications, predominantly manufactured in China and India, face potential repositioning due to US tariffs, while patented drugs, made in Ireland, Switzerland, and the USA, have different supply chain considerations. Sustainability as a Key Driver: Sustainability remains a significant concern, particularly for large companies with extensive supply chains, suggesting an ongoing focus on environmentally conscious practices within the industry. Learn More About Supply Chain Reset: Overcoming Pharma & Healthcare Supply Chain Challenges Michael Needham | LinkedIn Efficio | LinkedIn Efficio Transforming global procurement: Innovating digital solutions and partnership  Two transformations, one competitive edge: Procurement in Physician Practice Management  Re-designing procurement: A global healthcare manufacturer's post-acquisition journey  170+ million vaccines administered: The UK Vaccine Taskforce's digital supply planning transformation  Pharma and Healthcare: Avoid panic buying by approaching safety stocks wisely - | Efficio US  How the Inflation Reduction Act is shaping pharma procurement strategies - | Efficio US  The Logistics of Logistics Podcast If you enjoy the podcast, please leave a positive review, subscribe, and share it with your friends and colleagues. The Logistics of Logistics Podcast: Google, Apple, Castbox, Spotify, Stitcher, PlayerFM, Tunein, Podbean, Owltail, Libsyn, Overcast Check out The Logistics of Logistics on Youtube

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC's new vaccine advisors are meeting with an unexpected agenda today, including discussions on topics such as Sanofi and Gilead's protein degrader deals, the FDA's review of Sarepta's gene therapy, and a contentious hearing with RFK Jr. over vaccines. The meeting marks the beginning of a new era for the influential vaccine committee. The FDA has named a psychedelic proponent as CDER deputy director, while Nektar has declared a Phase IIb win for eczema treatment. Experts say conflicts of interest among axed ACIP members are a "red herring," and the pharma industry is facing turmoil in failed immuno-oncology projects. Prescription drug sales are projected to hit $1.75 trillion by 2030, thanks to GLP-1s. Transitioning to the next news, a major pharmaceutical company has announced a breakthrough in cancer research, potentially changing the landscape of treatment options for patients worldwide. This development comes at a time when the industry is seeing significant advancements in personalized medicine and targeted therapies. Moving on to regulatory updates, the FDA has recently approved a new drug for a rare disease, providing hope for patients who previously had limited treatment options. This decision showcases the agency's commitment to expediting the approval process for innovative therapies that address unmet medical needs. In other news, a biotech startup has secured funding for its groundbreaking technology that aims to revolutionize drug delivery methods. This investment highlights the growing interest in novel approaches to drug development and underscores the importance of innovation in the industry.Wrapping up today's episode, we take a look at the latest trends in digital health, with companies leveraging artificial intelligence and big data analytics to improve patient outcomes and streamline healthcare delivery. These technological advancements have the potential to transform the way healthcare is delivered and pave the way for a more efficient and patient-centric system. That's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology sectors.

In this episode, we sit down with Dr. Prateek Bhatia, Vice President & GM at Intrafusion by McKesson, to uncover his inspiring journey from being a pharmacy student in Pune, India to leading one of the most crucial verticals in the U.S. healthcare system. What you'll learn:– Key trends shaping the infusion therapy market – The biggest challenge health systems face today – Why infusion services are a critical part of modern care – Can India become the next big hub for infusion startups? – A rapid-fire round with fresh insights and fun!This is a must-watch for pharmacy students, young professionals, and anyone curious about global healthcare leadership and innovation.Stay tuned with us!Don't forget to like, comment, and subscribe for more insights on innovation and disruption in healthcare.#Gameofpharma #pharmapodcast #infusionindustry #pharmaindustryAvailable on YouTube, Spotify, Gaana, JioSaavn, Amazon Music, and Apple Podcasts. Dr. Prateek's LinkedIn: https://www.linkedin.com/in/prateek-bhatia/Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/Follow us on social media-Website: https://gameofpharma.com/Instagram: https://www.instagram.com/gameofpharma/LinkedIn: https://www.linkedin.com/company/game-of-pharma/

„Einmal Pharma – immer Pharma?“ Gemeinsam mit der Recruiting-Expertin Luise Liehr nimmt Podcast-Host Dominik Flener die Entwicklungen im Bewerbermarkt der Pharmaindustrie ins Visier. Dabei sprechen die beiden nicht nur über Fachkräftemangel, Gehalt und Recruiting-Prozesse, sondern über das, was darunter liegt: Haltung, Bereitschaft zum Wandel und die neue Realität im Pharma-Business.Dabei wird klar: Pharma-Recruiting 2025 bedeutet mehr als nur Jobbesetzung. Es geht um Erwartungsmanagement, Rollenverständnis, strategisches Matching – und die Fähigkeit, mit Offenheit und Energie auf Veränderungen zu reagieren. Ein ehrlicher Blick auf neue Anforderungen und alte Denkfehler.Highlights dieser Episode:Warum Fachkräftemangel kein Mythos, aber auch keine Ausrede ist.Wie sich GP-Außendienst neu positioniert – und warum das mehr als ein Trend ist.Was KAM & MSL voneinander lernen müssen – und wie die Zusammenarbeit von morgen aussieht.Welche Risiken entstehen, wenn Gehalt zur alleinigen Verhandlungsbasis wird.Warum die besten Bewerber:innen heute vor allem Klarheit suchen.Und wieso echte, ehrliche Energie im Team der entscheidende Unterschied bleiben wird.+++ Links zur Episode +++HCC Jobportal - www.hccjobs.at+++ Feedback & Social Media +++Du hast Feedback zu dieser Episode?Schreibe uns gerne an podcast@healthcarechangers.com.Folge dem Host Dominik FlenerLinkedIn | Facebook | InstagramFolge dem Healthcare Changers PodcastLinkedIn | Facebook | Instagram++++++

Send Vanessa a Text MessageIf you appreciate the work here and want to support Intentionally Well, consider becoming a monthly supporter below. Every bit helps keep meaningful conversations coming your way: Become a Monthly SupporterAlso, there's a one-time support link at the very bottom of this page you might want to check out. It's a simple way to show your support.In this powerful episode, I sit down with Dr. Adam Urato, a practicing Maternal-Fetal Medicine Specialist and Harvard-trained physician who is breaking the silence on what he has seen over decades of working with pregnant women and their babies.Dr. Urato has been on the front lines of high-risk pregnancies, and what he has witnessed compelled him to compassionately speak up. He is now actively challenging the FDA to update the labeling on SSRIs (commonly known as antidepressants), due to their potential impact on fetal development.But keep in mind, this conversation is not just for pregnant women.It is for anyone who has ever trusted a prescription, followed medical advice without question, or wondered why our healthcare system continues to spend more while producing some of the worst outcomes among developed nations.In this episode, we explore: • The real risks of antidepressant use during pregnancy • What the science actually says and why it is often buried • How regulatory bodies and pharmaceutical companies shape the narrative • Why informed consent is more critical than ever • How the system is working for profits, not healthThis episode is a must-listen for anyone who wants to make truly informed choices about their body, their healthcare, and their family.Connect with Dr. Adam Urato: • Learn more about Dr. Adam Urato on X Connect with Vanessa and the show:All My Favorites + Exclusive Discounts: Linktree Podcast on Instagram: @well.with.vanessaVanessa on Instagram: @thegiftofgoodsVanessa on Threads: @thegiftofgoodsPodcast on YouTube: @IntentionallyWellPodcastPodcast on TikTok: @well.with.vanessaPodcast on X (Twitter): @wellwithvanessaEmail: intentionallywellpodcast@gmail.comSupport the showPodcast Website: Intentionally Well with Vanessa LopezThis episode is for informational purposes only. Please consult a trusted health practitioner for individual concerns.

Monopolies! They're a problem as old as our country itself. On this week's TLDR, we talk to Denise Hearn and Vass Bednar, authors of The Big Fix: How Companies Capture Markets and Harm Canadians, about how Canadian companies got so big. And, we look at a surprising proposal for tackling the problem (at least in the airline industry). Plus, we explore how a new wonder drug could spell the end of the opioid epidemic. And, we watch as the pump and dump gets a makeover for the digital age.This episode was hosted by Devin Friedman, business reporter Sarah Rieger and former hedgefunder Matthew Karasz, with appearances by writers Vass Bednar and Denise Hearn. Follow us on other platforms, or subscribe to our weekly newsletter: linkin.bio/tldrThe TLDR Podcast is offered by Wealthsimple Media Inc. and is for informational purposes only. The content in the TLDR Podcast is not investment advice, a recommendation to buy or sell assets or securities, and does not represent the views of Wealthsimple Financial Corp or any of its other subsidiaries or affiliates. Wealthsimple Media Inc. does not endorse any third-party views referenced in this content. More information at wealthsimple.com/tldr.

In this episode of Medical Affairs unscripted, Peg Crowley-Nowick, PhD, MBA, Senior Advisor, Medical Affairs Consulting at Lumanity, and Cathy Symonds, PhD, Program Lead and Head of New Product Planning at Arbor Biotechnologies, engage in an insightful discussion about the evolving role of new product planning and its intersection with Medical Affairs. Peg and Cathy explore the strategic importance of new product planning in the lifecycle of medical products, emphasizing how early commercial strategy is essential for successful development and market entry. They discuss various frameworks and best practices, including the creation of a Target Product Profile (TPP), which helps align the team on what success looks like and guides the development process from early stages through to commercialization. The conversation delves into the critical partnerships between new product planning and other functions such as Medical Affairs, clinical development, and market access. They highlight how these collaborations are essential for gathering comprehensive insights from healthcare professionals, patients, and the broader market landscape. They share their experiences and perspectives on the importance of strategic narratives that communicate the value of new products effectively to both internal teams and external stakeholders, including investors. Throughout the discussion, they underscore the necessity of continuous planning and adaptation to ensure that products not only meet regulatory requirements but also achieve commercial success and ultimately improve patient outcomes.

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Summer of Soccer continues and in this fun episode Clay, Valair and Stephen are getting a crew togther... 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA's Center for Drug Evaluation and Research (CDER) head, Jacqueline Corrigan-Curay, is leaving the agency in July, becoming the latest in a series of FDA leaders to depart. Eli Lilly is facing concerns about gastrointestinal side effects for their weight loss pill, Orfoglipron, despite brushing off these worries. Vertex's cell therapy for diabetes shows promise, but questions remain about its market potential. HHS Secretary Robert F. Kennedy Jr. has restacked the CDC's vaccine advisory committee, claiming conflicts of interest within the previous group, which experts argue may impact the committee's apolitical nature. Prothena has downsized following a failure in an Al amyloidosis trial, and Novavax is adapting to regulatory uncertainty. Overall, the FDA is experiencing significant turnover in leadership, and challenges persist in drug development and regulation.

LINK TO ACRO'S RBQM SUMMARY REPORT: https://www.acrohealth.org/rbqm-summary-report/In this episode, ACRO RBQM Working Group members Lauren Garson (Veeva), Cris McDavid (Parexel), and Jennifer Stewart (Premier Research) joined ACRO's Good Clinical Podcast to discuss key takeaways from ACRO's annual RBM/RBQM Landscape Survey. Since 2019, ACRO's RBQM survey has dug into trial-level data on industry adoption of RBM and RBQM components. Informed by conversations with FDA, the aim of the survey is to evaluate ACRO member companies' adoption of risk-based monitoring to better understand how the larger framework of risk-based quality management (RBQM) are being adopted across the clinical trial industry.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Nicole Verdun has exited the FDA as CBER director, allowing Vinay Prasad to consolidate power within the agency. Prasad is seen as a stabilizing and trustworthy figure within the rapidly changing FDA, especially since the departure of Peter Marks in late March. Novavax is adapting to regulatory uncertainty following the delayed approval of its next-generation COVID-19 vaccine. The company is relying on agility and a diverse pipeline to navigate changing regulations. Additionally, the FDA has frozen trials shipping cells to countries like China due to new export control policies. Exemptions have allowed companies to ship biological materials overseas, but this practice is now being restricted. Zealand's GLP-1/GLP-2 drug has shown promising results in weight loss trials, with analysts believing there is potential for further improvement. Intellia Therapeutics aims to transform the lives of people with severe diseases through genome editing treatments. Overall, the biotech industry is facing various challenges and changes, requiring companies to stay adaptable and innovative.

What Cannes taught us about health creativity in 2025.Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register!    AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket!    Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

This episode originally aired as #327 on 5/20/23. It's an oldie but goodie so we are sharing it again! Mental Health is a mounting issue in America today.  Pharma prescriptions are higher than ever before, more people are in therapy than ever before and more than ever, people are searching for alternatives to those methods. On today's episode Jared runs through what he considers to be the foundational things that you should consider to improve your mental health. You will learn about the gut brain connection, deficiencies that impact mental health, the value of breath, sleep, water,  sunshine and more.Products:Precision Probiotic Vital SporesVital 5 Magnesium BisglycinateVital 5 Ultimate Vitality Multi-VitaminBioCoenzymated Active B ComplexVital 5 Omega 3 + AntioxidantsUltra Strength RX Omega 3Sensoril AshwagandhaAnxiety ReleaseVital SleepL-Theanine chewables Additional Information:Episode #164: Psychobiotics - Unique Probiotics for Depression, Anxiety and More Part 1Episode #166: Psychobiotics - Unique Probiotics for Depression Anxiety and More Part 2Episode #306: The Great Debate in Probiotics: Human Strains vs. SporesEpisode #258: Your Magnesium Users GuideEpisode #264: Jen's Story: How One Woman Fought Through Addiction, Mental and Physical Illness to Find Vitality.Episode #265: Sleep! Your Guide to Falling Asleep, Staying Asleep and Deeper and More Restful SleepVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

MDJ Script/ Top Stories for June 20th Publish Date:  June 20th    Commercial: From the BG AD Group Studio, Welcome to the Marietta Daily Journal Podcast.    Today is Friday, June 20th and Happy Birthday to Brian Wilson I’m Keith Ippolito and here are the stories Cobb is talking about, presented by Times Journal Sprayberry grad heads to Naval Academy Georgia Power offers energy efficiency resources to beat the summer heat Pharma company with major presence in Smyrna plans new factory Plus, Leah McGrath from Ingles Markets on Soda All of this and more is coming up on the Marietta Daily Journal Podcast, and if you are looking for community news, we encourage you to listen and subscribe!  BREAK: TOP TECH MECHANICAL STORY 1: Sprayberry grad heads to Naval Academy Daniel Silva, a Sprayberry High School graduate, earned a spot at the prestigious U.S. Naval Academy with a nomination from Sen. Jon Ossoff. Inspired by his Marine father, Silva dedicated himself to academic and leadership excellence, earning a $200,000 NROTC scholarship and founding Sprayberry’s men’s volleyball team. A first-generation Brazilian-American, Silva credits his family, faith, and mentors like Cmdr. Axel Spens for his success. He plans to major in computer science and become a Marine cyber officer, blending his passion for service with technology. Silva’s journey reflects resilience, community values, and a commitment to leadership, inspiring those around him. STORY 2: Georgia Power offers energy efficiency resources to beat the summer heat As summer begins, Georgia Power helps customers stay cool and manage energy bills with energy-saving tips and resources. Suggestions include changing air filters, sealing air leaks, using LED bulbs, and running appliances outside peak hours. The EASE Program offers free home upgrades for qualifying low-income households, while the My Power Usage tool tracks energy consumption and provides alerts to stay within budget. Customers can access local assistance for utilities, food, and shelter via GeorgiaPower.com/Assistance and explore income-based programs at GeorgiaPower.com/IQPortal. With tools, programs, and community partnerships, Georgia Power empowers customers to reduce energy costs and navigate summer efficiently. STORY 3: Pharma company with major presence in Smyrna plans new factory UCB, a Belgium-based biopharmaceutical company, announced plans to build a state-of-the-art drug manufacturing facility in the U.S., creating 300 permanent jobs and over 500 construction jobs. The facility, aimed at supporting UCB’s growing U.S. patient base, will have an estimated $5 billion economic impact. A feasibility study is underway to select a location prioritizing talent and innovation. UCB’s U.S. workforce has grown 73% since 2017, supported by $4.5 billion in investments and 15 FDA approvals. CEO Jean-Christophe Tellier emphasized the facility’s role in strengthening UCB’s supply chain, advancing innovation, and contributing to the U.S. biomedical and economic landscape. We have opportunities for sponsors to get great engagement on these shows. Call 770.799.6810 for more info.  Break: Ingles Markets 6 STORY 4: KSU police officer fired, charged with attacking colleague A Kennesaw State University police officer, Brandall Irving, 39, was fired and faces battery and false imprisonment charges after allegedly detaining a female staff member against her will. The incident occurred on June 3 at KSU’s Marietta campus, where Irving reportedly pushed the woman against a desk, blocked the door, and refused her repeated requests to leave. He also allegedly grabbed her arm when she tried to open the door. Following an internal investigation, Irving was terminated on June 6. Arrested the same day, he was charged with misdemeanor battery and felony false imprisonment, later released on a $10,000 bond. STORY 5: Lockheed announces reliability breakthrough for Marietta-made C-130s Lockheed Martin announced a significant breakthrough in the wing structure design of its C-130J Super Hercules aircraft, extending its lifespan by 40% to 122,500 flight hours. The new design, tested rigorously in a program funded by the U.S. and Royal Canadian Air Forces, exceeded expectations by simulating real-world flying conditions. Built at Lockheed’s Marietta plant, the C-130J is a tactical airlifter used by 28 operators across 23 nations, with over 560 units delivered and 3 million flight hours logged. Since 2009, the aircraft has featured an Enhanced Service Life center wing box, doubling its original 45,000-hour service life. Break: And now here is Leah McGrath from Ingles Markets on Soda We’ll have closing comments after this. Break: TIDWELL TREES Signoff-   Thanks again for hanging out with us on today’s Marietta Daily Journal Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at mdjonline.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com tidwelltrees.com toptechmech.com #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations See omnystudio.com/listener for privacy information.

In this illuminating episode of Quite Frankly, Frankie Val sits down with nutritionist Jay Gulinello for a powerful conversation on body sovereignty, metabolic dysfunction, and the spiritual war being waged through our food systems. Jay breaks down how decades of misinformation, processed foods, and synthetic ingredients have created a population that's overfed but dangerously undernourished, both physically and spiritually. Together, they examine the weaponization of food as a tool of control, how endocrine disruptors and seed oils are linked to chronic illness, and why the real war isn't just for your mind, but your metabolism. Jay shares actionable insights on returning to nutrient-dense, ancestral ways of eating, rejecting the lies of Big Food and Pharma, and reclaiming personal health in a system designed to keep us weak and dependent. This episode blends science, sovereignty, and truth-seeking in a way that will have you questioning everything you thought you knew about health. A must-listen for anyone ready to break free from the matrix and build true resilience from the inside out.

Karl and Erum are joined by Nancy Diniz, Co-Founder of bioMATTERS LLC, to explore the future of biodesign and sustainable materials. Drawing on her background in architecture and digital fabrication, Nancy unpacks how bioMATTERS is creating novel mycelium- and microbe-based materials that are not only biodegradable but alive. The conversation traverses speculative design, the challenge of scaling living materials, and the cultural shift needed to embrace biology as a partner in production. With humor and insight, Nancy shares how her work sits at the intersection of art, science, and ecology—and why the next generation of materials must be rooted in systems thinking.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 - From Kitchen Experiments to Living Systems: Nancy's DIY Biodesign Spark00:00:28 - Protests, Purpose, and Speaking Up in a Wild World00:02:10 - The Future Is Biotech: From AI in Pharma to Bio-powered Skin Care00:04:32 - L'Oreal Meets Nvidia: The Unexpected Longevity Alliance00:08:17 - Meet Nancy Diniz: Architect Turned Biodesign Trailblazer00:15:22 - Clay, Craft, and Mycelium: Where Earth Meets Engineered Biology00:21:13 - Breaking the Mold: How Nancy Navigates the Unknown in Biodesign00:23:45 - Happy Accidents: Why Biodesign Thrives on Trial and Error00:25:10 - New Frontiers: Biomanufacturing Takes Center Stage00:25:50 - When Design Dreams Collide with Biological Reality00:27:00 - The Ethics of Growing with Care in Biodesign00:29:44 - Meet Symbi: Nancy's Living Material with a Message00:32:10 - From Petri Dish to Production: The Real Challenge of Scale00:34:48 - What Ancient Pottery Can Teach Us About Tomorrow's Materials00:37:08 - Future Tools: What's Next in the Biodesign Toolkit00:40:00 - Dreaming Out Loud: Nancy's Vision for Biofuturistic Design00:42:24 - Start in the Kitchen: Nancy's Call to the Next Generation of Biodesigners00:44:25 - Final Reflections: Staying Curious in a Biotech WorldLinks and Resources:bioMatters founded by Nancy Diniz and Frank MelendezCentral Saint Martins MA Biodesign courseAncient Futures Exhibit, featuring bioMatters workROMANIA or HUNGARY Mushroom capMerck Digital Sciences StudiosL'Oréal teams up with NvidiaNucleus Genomics offers to optimize embryosNSCEB Roadshow Summer 2025BioDesign Challenge Genspace⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Topics Covered: biomanufacturing, cell free biomanufacturing, enzymes, nutraceuticals, biotech, pharmaceuticals, AI, spinoutsHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.

Exploring the Complexities of Pharma Rebates with Ann Lewandowski In this Summer Short episode of Relentless Health Value, host Stacey Richter converses again with Ann Lewandowski about the intricate dynamics of pharmaceutical rebates, or as Lewandowski prefers, post-sale concessions.  The discussion delves into the nuances of these rebates, the impact they have on drug costs, and the hidden consequences for patients and plan sponsors.  They highlight articles and insights by Austin Chelko and Peter Hayes, touching on how rebates can disadvantage the pursuit of lower-cost generics and biosimilars, and can obstruct pharmacogenetic testing that ensures drug efficacy and safety.  The conversation also critiques the opacity of rebates, deemed trade secrets by pharma and PBM companies, and underscores the ethical and financial dilemmas posed by the current rebate-driven system. === LINKS ===

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Ey's 2025 Biotech Beyond Borders report reveals that over one-third of biotech companies have less than a year of cash left, indicating financial challenges within the industry. The report emphasizes the need for a return to basics for biotech companies. Additionally, industry experts are discussing FDA Commissioner Makary's push to modernize the FDA and speed up regulatory processes. Scholar Rock has seen positive results with a weight loss combination therapy, and the FDA's new voucher program has been met with some optimism from biotech investors. Overall, the biotech industry is facing financial struggles, but there are opportunities for growth and innovation in the future.BioNTech and CureVac were once enemies, with BioNTech attacking CureVac's "failed" COVID vaccine program. However, they are now merging, with BioNTech buying CureVac in a $1.25 billion all-stock acquisition. The biopharma industry has seen a string of dramatic deals, with companies paying high premiums for acquisitions. This includes Sanofi paying a 300% premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. Overseas biosimilars companies can be sued in the US, potentially dissuading them from targeting the US market and benefiting domestic producers. Lilly's $1.3 billion acquisition of Verve in the gene editing space has been met with skepticism from analysts. Biotechs are seeking partnerships as the industry moves forward, with events like BIO2025 kicking off. The industry is facing challenges such as layoffs at companies like Lycia, while AstraZeneca makes a $5.3 billion AI bet with China's CSPC for chronic disease pills. Overall, the biopharma industry is experiencing a period of intense deal-making and strategic shifts.

Oft bereits Jahre vor der Diagnose weisen atypische Thrombosen, ein Herzinfarkt oder ein Schlaganfall darauf hin, was eigentlich nicht in Ordnung ist: zu viele Erythrozyten im Blut, zu viele Granulozyten, zu viele Blutplättchen. Die Rede ist von Polycythaemia vera, einer seltenen Blutkrebserkrankung. Die Diagnose wird oft spät gestellt, die therapeutischen Möglichkeiten werden teils nicht ausgeschöpft. Dabei haben die Patientinnen und Patienten eigentlich eine recht gute Prognose.

Health Insurance is Rigged & Controlled by the Big Companies w/ Donvan Ryckis of Ethos Benefits   - AZ TRT S06 EP10 (272) 6-15-2025              What We Learned This Week Health Insurance is primarily run by the Big 4 - BUCA: Blue Cross United Healthcare, CIGNA, Aetna To Insurance Co's – Premium = Revenue, and they are not going lower profits, so no incentive to lower costs Health insurance employer group plans can be broken down into 4 Parts Network PPO is what people typically think of when they think of health insurance There have been revisions to the Healthcare Act passed in 2021   Guest: Donovan Ryckis, Ethos Benefits https://ethosbenefits.com/   https://ethosbenefits.com/documentary/ https://businessofbenefitspodcast.com/   Our Ethos is Simple: Fiduciary First. Act in the best interest of those we serve—no matter the cost. ‘Ethos' represents the guiding principle, character, or spirit of a person or organization. It's the ‘why' that drives decision-making and fuel's purpose. Our Ethos is deeply rooted in the story of our Founder, Donovan Ryckis. Over a decade ago, Donovan, a fiduciary Series 65 securities advisor specializing in retirement and pension planning, was approached by a client facing a dire situation. The client's publicly traded broker claimed there was no solution for a staggering 37.5% health insurance renewal increase—a cost that threatened the business and its employees. With no prior experience in health insurance markets but guided by his unwavering fiduciary principles, Donovan took on the challenge. The result? He mitigated the risk entirely, delivering a solution 12% below the current rate. This allowed the business to thrive and ensured hundreds of employees wouldn't have to choose between basic necessities and skyrocketing health premiums. That moment sparked a revelation. The fraud, waste, and abuse Donovan had fought in retirement planning paled in comparison to the challenges in healthcare. He saw an opportunity to bring transparency and fiduciary principles to an industry in desperate need of change. Donovan pivoted his career, becoming one of the first fee-based health insurance advisors in the nation. By removing all conflicts of interest in broker compensation, he laid the foundation for what is now the leading innovative employee benefits agency in the country, delivering higher quality care at a significantly lower cost to employers nationwide.       Notes:   Ethos Benefits deals with employee benefits, with a primary focus on group health insurance   Per Donovan ‘Employee benefits are rigged'   Insurance company premium equals revenue. There is no incentive to lower cost, as it would lower profits.   ACA Obamacare passed in 2010, and it capped profits for insurance companies at 20%   Insurance Co's are working to expand their pool to make more profit   Health Insurance guarantees inflation keeps going up, so family of 4 could spend 35K a year   For a business, healthcare cost and employee benefits are a top 3 P&L expense   Ethos strategies can create a 30 to 40% reduction on premium impact to lower costs for a business   The HQ is in Florida, but they are a virtual office with agents and clients nationwide   Healthcare finance and delivery + Improving employee benefits     Seg 1   Donovan's bio, he was a financial advisor with a Series 65 license before he got into health insurance. Around 2014 he moved into health insurance seeing an opportunity for better service.   Typically you see agents who are working for the health insurance company and not really working for the employer companies they are selling to.   Health insurance is primarily run by the Big 4 – BUCA: Blue Cross United Healthcare, CIGNA, Aetna.   Health insurance employer group plans can be broken down into 4 Parts:   1.    TPA or third-party administrator 2.    Network PPO or HMO 3.    Pharmacy benefit RX 4.    Insurance that covers the caps the limits on the stop loss   PPO is your primary network and open on using referrals HMO is a non-preferred network typically has less offerings and tight on referrals   Ethos Benefits helps employers to break up the four parts of a group plan and customize   Network PPO is what people typically think of when they think of health insurance.   Network and the Big 4 health companies have a tighter deal with doctors and contract prices. A lot is pre-negotiated with a set of rates, which is the point of a PPO. This is where you get larger claims and they run in the system of healthcare.     Seg 2   Pay more for healthcare in the U.S. than the rest of the world   The biggest pharmaceutical companies are in the US Pharmaceutical companies in flight prices, and also set the prices They make money through spread pricing   Employers can actually pick up their own Pharma benefit and get the rebates that the big health insurance companies are not giving them   Healthcare system is a rigged game The fraud waste and abuse extremely high in health   401(k) and retirement benefit industry is actually tighter with more disclosure than the healthcare industry   Regulated better since the creation of the Securities Act in the 1930s and updates that ran through the 1970s and beyond with things like ERISA   There have been revisions to the healthcare act passed in 2021 - started in Jan.2022   Actions had 3 disclosures: ·         Brokers comp and bonus ·         Data with gag, clauses, and full access to data upon request ·         Benchmarking for drug cost     Further Notes via Google:   The revisions you are likely referring to are part of the Consolidated Appropriations Act of 2021 (CAA). While the CAA was passed in late 2020, many of its provisions, including those related to transparency in healthcare, became effective on January 1, 2022.  The three key areas of disclosure you mentioned are directly addressed within these regulations: 1.            Broker's Compensation and Bonuses: The CAA amends ERISA Section 408(b)(2) and requires service providers, including brokers, to disclose specific information to group health plan fiduciaries. 2.            Data Transparency (Gag Clauses and Full Access to Data): The CAA prohibits gag clauses, which prevent plans from providing access to their data. It also requires health insurance carriers to attest annually to their compliance with this prohibition. Moreover, the Health DATA Act, a proposed bill, would further reinforce the right of employers to access their data and hold service providers accountable for non-compliance. 3.            Benchmarking for Drug Costs: The CAA includes provisions regarding pharmacy benefit and drug cost reporting, which aims to provide greater transparency and potentially lead to better benchmarking of drug costs. The Build Back Better Act, a separate piece of legislation, also included provisions for Medicare to negotiate drug prices, further impacting drug costs and potential benchmarking.  These revisions aim to increase transparency in healthcare pricing and empower consumers and employers to make more informed decisions about their healthcare coverage.    Seg 3   Ethos works with Employers to create business plans usually with a 3 to 5 year time horizon. The goal is long-term to lower healthcare cost.   Example would be a company with 100 employees with 50 to 80% of them on the health plan (does not include dependents).   Ethos wants to keep the demands of a company low, easy transition.   Ethos handles employee Qs and healthcare navigation. Ethos is full service.   Risk handled 1 of 4 ways - Reduce, avoid, retain, transfer - Transfer to insurance   Broker wants to transfer risk Company can control costs Careful not to have too much disruption with a switch to a new company   Ex - start with pharmacy part NDC National Drug Code Run report vs costs   Pharmacy benefit mgr   Pre packaged health plan Gets co approved pharmacy benefit Save 5 - 15% on costs (30%)   Separate - parts of group plan     Seg 4   Brokers comp - incentives from big insurance companies   Opening move - edit pharmacy benefit piece   State by state - regulators and rules   Employers / employees Know the network and PPO   Nationwide covers insurance part – Stop-loss Insurance   30-40 major stop loss companies Ex: Allstate Met Life Sun Life   Stop-loss insurance for group health plans acts as a financial safety net for self-funded employers, protecting them from large, unpredictable medical claims. It is a form of additional insurance.   Healthcare risk is incredibly predictable on group basis   Overall predictable w stats, actuarial analysis   Gag clauses look at dataset from current carrier   Prescription database sets   3rd party admin are less of a concern, lots of claims   Average of 18 claims per employee per year, includes dependents   Data - review AI Claims analytics software   AI claims analytics software is transforming how insurance companies handle claims by leveraging artificial intelligence and machine learning to analyze data, automate tasks, and improve decision-making.    30 - 40% reduction in premium w Ethos     Further Notes via Google: Group Medical Plans Breakdown of the common components of a comprehensive employer group health plan, particularly within the context of a self-funded model.  Here's a more detailed explanation of each part: 1.            TPA (Third-Party Administrator): A TPA is a company that provides administrative services for self-funded health plans. This includes processing claims, handling enrollment, and managing other administrative tasks that would typically be done by an insurance company. 2.            Network (PPO or HMO): This refers to the group of doctors, hospitals, and other healthcare providers that the health plan contracts with to provide services to its members. The network defines where employees can go to receive care and often dictates the level of coverage they will receive (e.g., in-network vs. out-of-network benefits). ·                                             PPO (Preferred Provider Organization): Offers more flexibility, allowing members to see out-of-network providers, though with higher out-of-pocket costs. ·                                             HMO (Health Maintenance Organization): Typically requires members to stay within the network for covered services, except in emergencies.                 Pharmacy Benefit (RX): This component manages the prescription drug coverage for the plan. It includes negotiating drug prices, processing claims for prescriptions, and managing the plan's formulary (list of covered drugs).                 Stop-Loss Insurance: This is a crucial element for self-funded employers. It protects the employer from catastrophic claim costs. If an individual employee or the entire group's claims exceed a certain threshold (the "attachment point"), the stop-loss insurance kicks in to cover the excess costs, limiting the employer's financial liability.  Additional Considerations: ·                     Data Access: Self-funded plans often provide employers with greater access to claims data, which can be used to analyze healthcare costs, identify trends, and implement strategies to improve employee health and manage costs. ·                     Benchmarking: Employers can use claims data and industry benchmarks to compare their plan's performance to similar organizations and negotiate better rates with providers and other vendors. ·                     Wellness Programs: Some employers offer wellness programs to encourage employees to adopt healthy behaviors and potentially reduce healthcare costs. ·                     Essential Health Benefits (ACA Compliance): Group health plans must comply with the Affordable Care Act (ACA), which requires them to cover a list of essential health benefits, such as outpatient care, emergency services, hospitalization, and prescription drugs. ·                     Other Benefits: Group plans can also include other benefits, such as dental, vision, life insurance, and long- and short-term disability insurance.  Understanding these different parts is essential for employers to effectively manage their group health plan, control costs, and provide valuable benefits to their employees.      Investing Shows: https://brt-show.libsyn.com/category/Investing-Stocks-Bonds-Retirement       ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

[01:23:16 – 01:27:24] — Cholesterol Myth, Statins, and Cognitive Decline Refutes the link between cholesterol and heart disease, critiques the use of statins, and explains how they contribute to memory loss by impairing mitochondrial function. [01:40:53 – 01:43:33] — Spike Protein Damage and Fertility Concerns Links mRNA vaccine-induced spike protein accumulation in reproductive organs to a global fertility crisis, citing observed autoimmune diseases and turbo cancer cases post-vaccination.[01:53:29 – 01:58:27] — Treating Vaccine Clotting with Enzymes and NAC Outlines a protocol using enzymes like lumbrokinase and an enhanced NAC formulation to reverse microclotting and spike protein persistence in long-haul COVID patients.[01:58:29 – 01:59:39] — Bacteriophages and Antibiotic Resistance Praises bacteriophage therapy as a targeted alternative to antibiotics and criticizes its abandonment in favor of pharmaceuticals, linking this to rising antimicrobial resistance.[02:01:26 – 02:04:38] — SSRIs, Mental Health, and Nutrient Deficiencies Critiques widespread SSRI prescriptions, emphasizing magnesium, iodine, and vitamin D deficiencies as underlying causes of depression and anxiety in young patients.[02:14:43 – 02:17:31] — SSRI Withdrawal, Loneliness, and Atheism Trends Explores the challenges of getting off SSRIs, with emphasis on individualized treatment and social patterns such as loneliness, atheism, and lack of purpose among depressed patients.[02:26:27 – 02:29:41] — Immune System Boosting and Sunshine Debate Advocates sunlight and antioxidant synergy (e.g. ALA, vitamin C, CoQ10) as immune boosters; challenges conventional views on sunlight causing skin cancer, linking melanoma instead to lack of sun exposure.[02:31:28 – 02:40:14] — DMSO and Boron for Pain, Bone, and Hormonal Health Promotes DMSO combined with boron for arthritis and testosterone boosting; includes detailed background on absorption, safety, and additional applications.[02:40:15 – 02:45:19] — Leaky Gut as Root of Autoimmune Disease Describes how gluten-related intestinal damage can lead to autoimmune diseases like rheumatoid arthritis and Hashimoto's; outlines a multi-supplement gut-healing protocol.[03:00:25 – 03:03:54] — Medical Industrial Complex and Generational Health Decline Critiques a profit-driven healthcare model that fosters chronic illness for repeat business and links rising childhood illness and birth defects to vaccine exposure and poor nutrition.[03:06:12 – 03:17:16] — Thyroid Dysfunction and Comprehensive Testing Approach Explains the biochemical complexity of thyroid function and criticizes mainstream thyroid testing, advocating for broader lab panels and natural hormone therapies.[03:20:16 – 03:23:19] — Blue Light, Circadian Rhythm, and Melatonin Suppression Describes how artificial lighting and sunglasses disrupt melatonin production, emphasizing the need for natural sunlight exposure and avoidance of electronics during sleep.[03:48:28 – 03:52:20] — Economic Collapse, Oil Crisis, and CBDC Transition Argues that current global conflict and economic chaos are engineered to collapse the dollar, spike oil prices, and drive public acceptance of central bank digital currencies.[03:59:24 – 04:00:05] — Grassroots Support for Independent Media Encourages community-driven funding of alternative media, rejecting corporate censorship and highlighting the role of listener support in sustaining truthful broadcasting. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:23:16 – 01:27:24] — Cholesterol Myth, Statins, and Cognitive Decline Refutes the link between cholesterol and heart disease, critiques the use of statins, and explains how they contribute to memory loss by impairing mitochondrial function. [01:40:53 – 01:43:33] — Spike Protein Damage and Fertility Concerns Links mRNA vaccine-induced spike protein accumulation in reproductive organs to a global fertility crisis, citing observed autoimmune diseases and turbo cancer cases post-vaccination.[01:53:29 – 01:58:27] — Treating Vaccine Clotting with Enzymes and NAC Outlines a protocol using enzymes like lumbrokinase and an enhanced NAC formulation to reverse microclotting and spike protein persistence in long-haul COVID patients.[01:58:29 – 01:59:39] — Bacteriophages and Antibiotic Resistance Praises bacteriophage therapy as a targeted alternative to antibiotics and criticizes its abandonment in favor of pharmaceuticals, linking this to rising antimicrobial resistance.[02:01:26 – 02:04:38] — SSRIs, Mental Health, and Nutrient Deficiencies Critiques widespread SSRI prescriptions, emphasizing magnesium, iodine, and vitamin D deficiencies as underlying causes of depression and anxiety in young patients.[02:14:43 – 02:17:31] — SSRI Withdrawal, Loneliness, and Atheism Trends Explores the challenges of getting off SSRIs, with emphasis on individualized treatment and social patterns such as loneliness, atheism, and lack of purpose among depressed patients.[02:26:27 – 02:29:41] — Immune System Boosting and Sunshine Debate Advocates sunlight and antioxidant synergy (e.g. ALA, vitamin C, CoQ10) as immune boosters; challenges conventional views on sunlight causing skin cancer, linking melanoma instead to lack of sun exposure.[02:31:28 – 02:40:14] — DMSO and Boron for Pain, Bone, and Hormonal Health Promotes DMSO combined with boron for arthritis and testosterone boosting; includes detailed background on absorption, safety, and additional applications.[02:40:15 – 02:45:19] — Leaky Gut as Root of Autoimmune Disease Describes how gluten-related intestinal damage can lead to autoimmune diseases like rheumatoid arthritis and Hashimoto's; outlines a multi-supplement gut-healing protocol.[03:00:25 – 03:03:54] — Medical Industrial Complex and Generational Health Decline Critiques a profit-driven healthcare model that fosters chronic illness for repeat business and links rising childhood illness and birth defects to vaccine exposure and poor nutrition.[03:06:12 – 03:17:16] — Thyroid Dysfunction and Comprehensive Testing Approach Explains the biochemical complexity of thyroid function and criticizes mainstream thyroid testing, advocating for broader lab panels and natural hormone therapies.[03:20:16 – 03:23:19] — Blue Light, Circadian Rhythm, and Melatonin Suppression Describes how artificial lighting and sunglasses disrupt melatonin production, emphasizing the need for natural sunlight exposure and avoidance of electronics during sleep.[03:48:28 – 03:52:20] — Economic Collapse, Oil Crisis, and CBDC Transition Argues that current global conflict and economic chaos are engineered to collapse the dollar, spike oil prices, and drive public acceptance of central bank digital currencies.[03:59:24 – 04:00:05] — Grassroots Support for Independent Media Encourages community-driven funding of alternative media, rejecting corporate censorship and highlighting the role of listener support in sustaining truthful broadcasting. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In this episode of Let's Combinate, host Subhi Saadeh is joined by Kirk Petyo, Managing Partner at Talent Factory Medical and founder of Talent Factory Recruiting. If you're a bioengineering student, recent grad, or early-career professional trying to break into medical devices, biotech, or pharma—this one's for you.With extensive experience recruiting for regulated industries like aerospace, medical devices, and pharmaceuticals, Kirk offers grounded, actionable insights for early-career professionals and hiring managers alike.This episode covers how to craft a strong resume, the importance of knowing your career “why,” how to stand out to recruiters, and why onshoring and shifting regulatory trends matter for the next generation of talent in life sciences.Timestamps00:00 – Welcome and Guest Introduction 00:35 – Kirk's Career Journey and Advice 02:18 – Navigating Early Career Challenges 03:12 – Building a Strong Resume and Networking 04:38 – The Importance of Specificity in Job Applications 08:56 – Recruitment Insights and Industry Trends 12:05 – Personal Experiences and Lessons Learned 18:49 – Advice for Upcoming Graduates 23:18 – The Importance of Passion in Job Interviews 24:00 – Evaluating Candidates Beyond Experience 24:58 – Personal Stories and Career Choices 30:55 – Bioengineering vs. Mechanical Engineering 41:34 – Industry Trends and Onshoring 44:18 – Entry-Level Opportunities and Recruitment About Kirk PetyoKirk Petyo is the Managing Partner at Talent Factory Medical and founder of Talent Factory Recruiting. He has spent his career recruiting top talent in highly regulated industries like aerospace, medical devices, biotech, and pharma. Known for his ability to bridge business needs with real human connections, Kirk helps companies grow stronger teams—and helps candidates navigate complex career decisions with clarity and purpose.About the Host Subhi Saadeh is a Quality Professional and host of Let's ComBinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large Medical Device and Pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics.Subhi currently serves as the International Committee Chair for the Combination Products Coalition (CPC), is a member of ASTM Committee E55, and has served on AAMI's Combination Products Committee.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly's acquisition of Verve Therapeutics for $1.3 billion has sparked interest in the gene editing space, with analysts speculating on potential market boosts. Recent M&A activity in the biopharma sector has accelerated, despite challenges from drug pricing policies and tariff threats. In other news, a court order has restored canceled NIH grants, and a CDC scientist has resigned over vaccine regulation concerns. Updates on various biotech developments, including Intellia Therapeutics' aim to develop genome editing treatments for severe diseases, are also making headlines.Stay tuned for more updates on the latest developments in the pharmaceutical industry.

Medical marketing has officially been honored at the 2025 Cannes Lions International Festival of Creativity!The Pharma, Health and Wellness Lions as well as the Lions Health and United Nations Grand Prix for Good were doled out Monday.Additionally, IPG Health reigned supreme once again, as FCB Health was named Healthcare Network of the Year and Area 23 was named Healthcare Agency of the Year.This week, we hear from editor-in-chief Jameson Fleming from on-the-ground in France, while managing editor Jack O'Brien, pharma editor Lecia Bushak and reporter Heerea Rikhraj delve into the health brands, medical marketing agencies and work that won in Cannes. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

India's retail investors are betting on turnaround stories to make a windfall, new wave of IPOs to hit markets but timelines can be upset by global conflict, Indian drugmakers are preparing strategic growth plans amid trade uncertainties and Vodafone Idea teams up to take mobile connectivity to remote regions. Tune in to all this and more exclusives on Moneycontrol Editor's Picks.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

MD is joining in on the lawsuit against big Pharma. Alligator outside of a motel in VA. 988 hotline in Baltimore.  Make sure to also keep up to date with ALL our podcasts we do below that have new episodes every week:The Thought ShowerLet's Get WeirdCrisis on Infinite Podcasts

In this episode, we delve into the intersection of AI and pharma, uncovering how artificial intelligence is set to change drug discovery and its impact on investing. Learn what this means for the future of healthcare and your investment portfolio.   Disclosure: The views expressed are those of the speaker and are subject to change at any time. These views are for informational purposes only and should not be relied on as a recommendation to purchase any security or as an offer of securities or investment advice. No forecast can be guaranteed. Past performance is no guarantee of future results.   Unless otherwise indicated, logos and product and service names are trademarks of MFS® and its affiliates and may be registered in certain countries. Distributed by: U.S. – MFS Institutional Advisors, Inc. ("MFSI"), MFS Investment Management and MFS Fund Distributors, Inc., Member SIPC.; Latin America – MFS International Ltd.; Canada – MFS Investment Management Canada Limited. No securities commission or similar regulatory authority in Canada has reviewed this communication; Note to UK and Switzerland readers: Issued in the UK and Switzerland by MFS International (U.K.) Limited ("MIL UK"), a private limited company registered in England and Wales with the company number 03062718, and authorised and regulated in the conduct of investment business by the UK Financial Conduct Authority. MIL UK, an indirect subsidiary of MFS®, has its registered office at One Carter Lane, London, EC4V 5ER.  Note to Europe (ex UK and Switzerland) readers: Issued in Europe by MFS Investment Management (Lux) S.à r.l. (MFS Lux) – authorized under Luxembourg law as a management company for Funds domiciled in Luxembourg and which both provide products and investment services to institutional investors and is registered office is at S.a r.l. 4 Rue Albert Borschette, Luxembourg L-1246. Tel: 352 2826 12800. For readers in Saudi Arabia, Kuwait, Oman, and UAE (excluding the DIFC and ADGM) and Bahrain readers. In Qatar strictly for sophisticated investors and high net worth individuals only. In Bahrain, for sophisticated institutions only: The information contained in this document is intended strictly for professional investors. The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of MFS international U.K. Ltd ("MIL UK"). The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser. Please note that any materials sent by the issuer (MIL UK) have been sent electronically from offshore. South Africa: This document, and the information contained is not intended and does not constitute, a public offer of securities in South Africa and accordingly should not be construed as such. This document is not for general circulation to the public in South Africa. This document has not been approved by the Financial Sector Conduct Authority and neither MFS International (U.K.) Limited nor its funds are registered for public sale in South Africa. This material shall not be circulated or distributed to any person other than to professional investors (as permitted by local regulations) and should not be relied upon or distributed to persons where such reliance or distribution would be contrary to local regulation; Singapore – MFS International Singapore Pte. Ltd. (CRN 201228809M); Australia/New Zealand - MFS International Australia Pty Ltd ("MFS Australia") (ABN 68 607 579 537) holds an Australian financial services licence number 485343. MFS Australia is regulated by the Australian Securities and Investments Commission.; Hong Kong - MFS International (Hong Kong) Limited ("MIL HK"), a private limited company licensed and regulated by the Hong Kong Securities and Futures Commission (the "SFC"). MIL HK is approved to engage in dealing in securities and asset management regulated activities and may provide certain investment services to "professional investors" as defined in the Securities and Futures Ordinance ("SFO").; For Professional Investors in China – MFS Financial Management Consulting (Shanghai) Co., Ltd. 2801-12, 28th Floor, 100 Century Avenue, Shanghai World Financial Center, Shanghai Pilot Free Trade Zone, 200120, China, a Chinese limited liability company registered to provide financial management consulting services.; Japan - MFS Investment Management K.K., is registered as a Financial Instruments Business Operator, Kanto Local Finance Bureau (FIBO) No.312, a member of the Investment Trust Association, Japan and the Japan Investment Advisers Association. As fees to be borne by investors vary depending upon circumstances such as products, services, investment period and market conditions, the total amount nor the calculation methods cannot be disclosed in advance. 65116

US President Trump says he wants "a real end," with Iran "giving up entirely" on nukes”, via CBS's Jacobs.US President Trump says the EU is not yet offering a fair deal, there is a chance of a deal with Japan but they are "tough". Pharma tariffs coming soon.Stocks hit as Iran-Israel strikes continue and Trump posts that "everyone" should evacuate Tehran.FX markets in narrow ranges awaiting US Retail Sales; incremental strength in JPY post-BoJ, but Ueda sparked some weakness thereafter.Two-way action for JGBs; USTs just about firmer while EGBs & Gilts reside in the red.Crude moves higher as Trump cuts his G7 trip short and now awaiting developments from the situation in Iran.Looking ahead, US Export/Import Prices, Retail Sales, Industrial Production, BoC Minutes, G7 Leaders' Summit.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics faced a drop in shares due to a second death from acute liver failure in a patient receiving their DMD gene therapy. On the other hand, Sage Therapeutics had a positive outcome with a $795 million acquisition by Supernus, surpassing a bid from Biogen. Meanwhile, Lilly saw promising results in a phase I study of their amylin/tirzepatide combo for weight loss. J&J's dual-targeting CAR T-cell therapy showed an 80% complete response rate in early lymphoma studies, demonstrating potential in the field. In addition, Intellia Therapeutics is dedicated to developing potentially curative genome editing treatments for severe diseases, showing promise for future advancements in healthcare.

TODAY ON THE ROBERT SCOTT BELL SHOW: Pharma Profits vs. Kids, SNAP Junk Food Ban, Drug Ad Crackdown, Microplastic Detox, Geranium Maculatum, WV Vax Exemption Clash, Lawsuit Shield Defeated, Executive Orders vs. Pharma, Chimps Mask Up, Psilocybin for Preachers and MORE! https://robertscottbell.com/pharma-profits-vs-kids-snap-junk-food-ban-drug-ad-crackdown-microplastic-detox-geranium-maculatum-wv-vax-exemption-clash-lawsuit-shield-defeated-georgia-protects-pesticide-manufactures-execut/https://boxcast.tv/view/pharma-profits-vs-kids-microplastic-detox-geranium-maculatum-vax-exemption-clash-chimps-mask-up-psilocybin-for-preachers---the-rsb-show-6-13-25-lqap9e1nqxmc0cd2o3si Please read this disclaimer carefully before you (“you”, “your”) use our [Your Website URL] website (“website”, “service”) operated by the [Your Business Name] (“operator”, “us”, “we”, “our”). Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

In this episode, Chad Robichaux is joined by healthcare reformer & founder of Ways2Well, Brigham Buhler.Brigham uncovers the truth about the pharmaceutical industry, insurance company kickbacks, & why effective treatments like Ibogaine, stem cells, and peptides are being suppressed. He shares his personal journey from launching Cialis as a young pharma rep to walking away from the industry after seeing how off-label promotion, lobbying, and corporate greed were harming patients, especially veterans.He also breaks down the FDA's role in blocking alternative therapies, the corrupt relationship between PBMs and Big Pharma, and how he's fighting back through legislation and his own medical companies. If you've ever felt like the system is stacked against your health, this conversation will open your eyes.Brigham Buhler is the founder and CEO of Ways2Well and Revive Pharmacy. A former pharmaceutical rep, he's now a leading voice in the fight for patient-first, preventative care and healthcare transparency. His testimony before the Senate, viral appearance on Joe Rogan, and ongoing collaboration with leaders like RFK Jr. have made him one of the most trusted names in healthcare reform today.Learn more about Brigham & Ways2Well: https://ways2well.comFollow Brigham: https://www.instagram.com/brigham.buhlerRESILIENT:Live Resilient Store: https://theresilientshow.com/live-resilient-storeJoin Our Patreon: https://patreon.com/theresilientshowFollow Us On Instagram: https://www.instagram.com/resilientshowFollow Us On Twitter:⁠ https://twitter.com/resilientshowFollow Us On TikTok: ⁠https://www.tiktok.com/@resilientshowFollow Chad:⁠https://www.instagram.com/chadrobo_official⁠https://www.x.com/chadroboSPONSORS:Smith & Wesson: ⁠https://www.smith-wesson.com/⁠Vortex Optics:https://vortexoptics.comGatorz Eyewear: ⁠https://www.gatorz.com/⁠Allied Wealth:https://alliedwealth.comBioPro+: ⁠https://www.bioproteintech.com/⁠BioXCellerator:https://www.bioxcellerator.comThe Holy Waters:https://theholywaters.comGet The Resilient Show x Uncharted Supply Co Bag: https://liveresilient.com/shopTRS is a proud supporter of military & first responder communities in partnership with Mighty Oaks Foundation.

In 2024, ACRO announced its D&I Site Resource Grants Program. Designed to support an innovative 12-month pilot project, the site resource grants act as a platform to incubate innovative strategies for improving representative enrollment in clinical research.  On this episode, site grantee representatives Dr. Ammara Mushtaq, MD (Brooklyn Clinical Research), Dr. Lovie Negrin, APRN (Randomize Now), and Sandra Carmona Torres, BSN (K2 Medical Research) join the podcast to discuss the lessons learned through implementing their pilot projects so far. They dive deeper into how sites can address barriers to participation, the need for consistent investment in building trust and engaging local community members, and the state of clinical research from a site perspective.

Jill Ellul has over 30 years of experience in the pharmaceutical industry and is the Founder & Managing Director of Mojoco, a business consultancy that offers innovation-led solutions to the Pharma, MedTech, and Biopharma sectors. Hear how to boost innovation & creativity in your organisation, how to dissolve groupthink, whether generative AI helps or hurts innovation, how to keep innovation the priority in your organisation, and whether all industries have room to be innovative. Connect with Shirley at ShirleyKavanagh.com and on LinkedIn, and Jill at MeetMojoco.com and on LinkedIn

Click here to send Ryan a text message!Episode #374This week saw Israel launch a massive airstrike on Iran, killing top IRGC leaders and exposing major defense vulnerabilities, prompting Trump to warn Iran to “make a deal before it's too late.” RFJ Jr. purges the CDC Vaccine Advisory Board. 17 China-linked VPN's in Apple and Google App stores. Plus much more on this week's weekly briefing.This episode covers:Israel's Massive Airstrike on Iran – 200+ targets hit, top commanders killed, nuclear sites damaged.Trump Warns Iran: Make a Deal or Else – Post-strike pressure as diplomacy clock runs out.U.S. Military Parade Ignites “No Kings” Protests – Over 1,500 protests across all 50 states.RFK Jr. Removes All 17 CDC Vaccine Board Members – Major shakeup over Pharma ties.China-Linked VPNs Still in U.S. App Stores – Tech watchdogs sound alarm on privacy risks.Agroterrorism & Biolab Smuggling – Chinese worms, pathogens, and FDA-approved threats.Congressional Stock Trades Surge After “Liberation Day” – Insider advantage exposed again.Trump Regains Control of California National Guard – Legal clash during LA immigration riots.Greta Thunberg Detained Near Gaza – Climate activist intercepted aboard protest boat.India Plane Crash Kills 241 – One of the deadliest aviation disasters in recent memory.HowToGrowYourFaith.com >> Learn the 5 Biggest Mistakes Christians Make In Their Walk With God (and how you can avoid them!)Sharable Episode Links (scroll down or search for this episode):Ryan's Website Buzzsprout Link MORE FROM RYAN:FREE DOWNLOAD: 21 Days to a Spirit-Led Life Subscribe on YouTubeTwitter | Instagram | LinkedInSubmit a question or topic for the podcast at ryanshoward.com/contactGet Ryan's eCourse & Coaching ProgramsSupport the show

Nurses Out Loud with Nurse Michele, RN – The trio tackles big topics with precision — from the fear-fueled measles resurgence narrative to the involvement of psy-op brigades, such as the 77th, in shaping online discourse. They expose influencers who act more like digital enforcers of pharmaceutical dogma than open-minded medical professionals. Using satire, sourced science, and fearless speech...

Nurses Out Loud with Nurse Michele, RN – The trio tackles big topics with precision — from the fear-fueled measles resurgence narrative to the involvement of psy-op brigades, such as the 77th, in shaping online discourse. They expose influencers who act more like digital enforcers of pharmaceutical dogma than open-minded medical professionals. Using satire, sourced science, and fearless speech...

Today at 11:11 am CST, on the Flyover Conservatives show we are tackling the most important things going on RIGHT NOW from a Conservative Christian perspective!  Today at 11:11 am CST, on the Flyover Conservatives show we are tackling the most important things going on RIGHT NOW from a Conservative Christian perspective!  TO WATCH ALL FLYOVER CONSERVATIVES SHOWS - https://flyover.live/show/flyoverTO WATCH ALL FLYOVER CONSERVATIVES SHOWS - https://flyover.live/show/flyoverTO WATCH ALL FLYOVER CONTENT: www.flyover.liveTO WATCH ALL FLYOVER CONTENT: www.flyover.liveTo Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To To Schedule A Time To Talk To Dr. Dr. Kirk Elliott Go To ▶ https://flyovergold.com▶ https://flyovergold.comOr Call 720-605-3900 Or Call 720-605-3900 ► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.com► Receive your FREE 52 Date Night Ideas Playbook to make date night more exciting, go to www.prosperousmarriage.comwww.prosperousmarriage.comCorey DeAngelisCorey DeAngelisBOOK: https://a.co/d/c6fc6umBOOK: https://a.co/d/c6fc6umTWITTER: www.x.com/deangeliscoreyTWITTER: www.x.com/deangeliscoreywww.x.com/deangeliscoreyDr. Troy SpurrillDr. Troy SpurrillWEBSITE: www.officialsynapse.com WEBSITE: www.officialsynapse.com --------------------------------------------------------------------------------------

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The global market for obesity drugs is expanding. Our U.S. Pharma and Biotech Analyst Terrence Flynn discusses what's driving the next stage of global growth for GLP-1 medicines.Read more insights from Morgan Stanley.----- Transcript -----Terrence Flynn: Welcome to Thoughts on the Market. I'm Terrence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. The market for obesity medicines is at an inflection point, and today I'll focus on what's driving the next stage of global growth.It's Thursday, June 5th at 2pm in New York.GLP-1 medicines have been viewed by many stakeholders as one of the most transformative medications in the market today. They've exploded in popularity over the last few years and become game changers for many people who take them. These drugs have large cap biopharma companies racing to innovate. They've had ripple effects on food, fitness, and fashion. They truly are a major market force. And now we're on the cusp of a significant broadening of use of these medicines.Currently the U.S. is the largest consumer in the world of GLP-1s. But new versions of these medicines suggest that this market will extend beyond the U.S. to significantly larger numbers of patients globally. On our estimate, the Total Addressable Market or TAM for obesity medications should reach $150 billion globally by 2035, with approximately [$]80 billion from the U.S. and [$]70 billion from international markets.Now this marks a meaningful increase from our 2024 forecast of [$]105 billion and reflects a greater appreciation of opportunities outside of the U.S. We think obesity drug adoption will likely accelerate as patients and providers become more familiar with the new products and as manufacturers address hurdles in production, distribution, and access.Current adoption rates of GLP-1 treatments within the eligible obesity population are about 2 to 3 percent. This is in the U.S., and roughly 1 percent in the rest of the world. Now, when we look out further, we anticipate these figures to surge to 20 percent and 10 percent respectively, really driven by five things.First, after a period of shortages, supply constraints have improved, and the drug makers are investing aggressively to increase production. Second new data show that obesity drugs have broader clinical applications. They can be used to treat coronary heart disease, stroke, hypertension, kidney disease, or even sleep apnea. They could also potentially fight Alzheimer's disease, neuropsychiatric conditions, and even cancer.Third, we think coverage will expand as obesity drugs are approved to treat diseases beyond obesity. Public healthcare coverage through Medicare should also broaden based on these expected approvals. Fourth, some drug makers are successfully developing obesity drugs, in pill form instead of injectables. Pills are of course easier to administer and can reach global scale quickly. And finally, drug makers are also developing next gen medications with even higher efficacy, new mechanisms of action, and more convenient, less frequent dosing.All in all, we think that over the next decade, broader GLP-1 adoption will extend well beyond biopharma. We expect significant impacts on medical technology, healthcare services, and consumer sectors like food, beverages, and fashion, where changes in patient diets could reshape market dynamics.Thanks so much for listening. If you enjoy the show, please leave us a review wherever you listen. And share Thoughts on the Market with a friend or colleague today.

Many topics today! First: FDA tentatively approves Moderna's new mRNA shot for Covid. What? And also why? Bret has six main points, which include discussion of mucosal immunity, IgG4, auto-immunity, long-term consequences, statistical tricks, and homeopathy. Then: how do we know what is true, and how can we avoid jumping to conclusions when triggered by language or circumstances that seem familiar and frustrating?...As explored through the story of Algerian boxer Imane Khelif, who has a Disorder of Sexual Development, won Olympic gold for beating women, but is definitely male. Finally: brief discussions of Glenn Greenwald, and Richard Dawkins. No, Dawkins, religion is not a mental infection.*****Our sponsors:CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at http://JoinCrowdHealth.com to get 1st 3 months for $99/month.ARMRA Colostrum is an ancient bioactive whole food that can strengthen your immune system. Go to http://www.tryarmra.com/DARKHORSE to get 15% off your first order.Helix: Excellent, sleep-enhancing, American-made mattresses. Go to www.HelixSleep.com/DarkHorse for 20% Off sitewide.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Moderna press release: https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-U-S--FDA-Approval-for-COVID-19-Vaccine-mNEXSPIKE/default.aspxKennedy on FDA and Moderna shot: https://x.com/seckennedy/status/1930012848056365294Mary Talley Bowden MD on the shots: https://x.com/mdbreathe/status/1927899248575545501Heather on Imane Khelif: https://x.com/HeatherEHeying/status/1929920193771516423Greenwald on the situation: https://x.com/ggreenwald/status/1928440222771015912Dawkins on religion: https://x.com/richarddawkins/status/1930184916190257320Support the show